Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
Pfizer Inc. has made its first M&A move since the planned mega-deal with Allergan PLC collapsed. The big pharma announced May 16 that it will buy Anacor Pharmaceuticals Inc. for $99.25 per share in cash, or approximately $5.2bn.
You may also be interested in...
Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.
Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.
Pfizer’s Eucrisa is one of the first new drugs to launch for the treatment of atopic dermatitis in more than a decade. The launch reflects an expansion strategy by Pfizer to move into a new therapeutic area – dermatology.